Steve Schonfeld’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Steve Schonfeld’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-126,500	Closed	-$4.05M	–	3303
2022 Q1	$4.05M	Buy	+126,500	New	+$3.63M	0.04%	500
2018 Q2	–	Sell	-5,910	Closed	-$489K	–	1040
2018 Q1	$489K	Buy	+5,910	New	+$670K	0.04%	480

Other funds holding SRRA

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Steve Schonfeld's SRRA Position: Q2 2022 in Review

Steve Schonfeld sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 126,500 shares — an estimated $4.05M sold.

Steve Schonfeld first reported a position in SRRA in Q1 2018 and held it in 2 quarters. The position peaked at $4.05M in Q1 2022. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

Steve Schonfeld reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Steve Schonfeld sold 126,500 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $4.05M.
Steve Schonfeld first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
Steve Schonfeld's Sierra Oncology, Inc. Common Stock position peaked at $4.05M in Q1 2022.
109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.